Cellmid Limited

Cellmid Limited (ASX:CDY) is an Australian biotechnology company developing first in class antibodies against the novel target midkine (MK).

Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the growth factor midkine (neurite growth-promoting factor 2). Midkine is an extensively validated therapeutic and diagnostic target in cancer, inflammation and auto-immune disorders.

Cellmid is actively seeking partners to commercialise these significant intellectual property assets in cancer, ischemia, and inflammatory diseases.